Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Check Point Inhibition in Muscle-Invasive Bladder Cancer

June 1st 2016

Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer

June 1st 2016

First-Line Options in Muscle-Invasive Bladder Cancer

June 1st 2016

Abiraterone Plus Prednisone in CRPC: Factors to Consider

June 1st 2016

CRPC: Patient Selection in AR-Directed Therapies

June 1st 2016

Therapeutic Options in Metastatic CRPC

June 1st 2016

Safety of Low-Dose Steroids with Abiraterone in Prostate Cancer

June 1st 2016

Potential Predictive Markers in Prostate Cancer

June 1st 2016

Candidacy for Chemotherapy in Oligometastatic Prostate Cancer

June 1st 2016

Local and Systemic Therapeutic Options in Low-Volume Prostate Cancer

June 1st 2016

Combining Radium-223 With Other Therapies in Prostate Cancer

June 1st 2016

Factors Impacting Treatment Approach in Advanced Prostate Cancer

June 1st 2016

Defining Symptomatic in Prostate Cancer

June 1st 2016

Treatment of Bone Metastases in Prostate Cancer

June 1st 2016

Dr. Barbieri on SPOP Mutations in Prostate Cancer

May 31st 2016

Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer genomics, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the implications of SPOP mutations in patients with prostate cancer.

FDA Approves Radioactive Imaging Agent Axumin in Recurrent Prostate Cancer

May 27th 2016

The radioactive imaging agent, fluciclovine F18 (Axumin), was approved by the FDA for use in positron emission tomography scans in men with suspected recurrence of prostate cancer whose prostate-specific antigen levels rise following prior treatment.

Gene Expression Signature Predicts Hormonal Resistance in Prostate Cancer

May 24th 2016

Using the Decipher Prostate Cancer Classifier assay to predict which patients might respond to hormonal therapy has resulted in the discovery and validation of an adjuvant androgen-deprivation therapy resistance signature.

Retreatment With Radium-223 Found Safe in mCRPC

May 21st 2016

Luke Nordquist, MD, discusses a study investigating a higher dose of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and the ongoing potential of the agent in treating the disease.

Dr. Jim Hu on Reevaluating PSA and the PLCO Trial

May 19th 2016

Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses critical flaws in the landmark PLCO trial in prostate cancer.

Sartor Discusses the Evolving Role of Biomarkers in Prostate Cancer

May 15th 2016

Oliver Sartor, MD, discusses current research with biomarkers in prostate cancer, as well as how some treatments may be utilized as both single agents and in combination.